Methods and compositions for engineering immunity

Patent metadata

Field	Value
Publication number	US-10639383-B2
Application number	US-201615357772-A
Country	US
Kind code	B2
Filing date	Nov 21, 2016
Priority date	Nov 23, 2015
Publication date	May 5, 2020
Grant date	May 5, 2020

Abstract

Nucleases and methods of using these nucleases for expressing an antibody from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.

First claim

What is claimed is:

1. A method of expressing, in a mammalian liver cell, an antibody, wherein the antibody binds to a protein expressed in the brain, wherein the protein is selected from the group consisting of a cancer antigen, a cellular receptor, a cytokine, a growth factor, a growth factor receptor, a kinase inhibitor, an integrin, α-synuclein, an amyloid protein, and a complement protein, the method comprising,
administering to the liver cell (i) an adeno-associated viral (AAV) vector comprising a transgene encoding the antibody, wherein the antibody is a single chain fragment variable (ScFv), an intrabody or a diabody and (ii) one or more AAV vectors comprising sequences encoding a pair of zinc finger nucleases that cleave an endogenous albumin gene in the liver cell, such that the transgene is integrated into the liver cell and the liver cell produces and secretes the antibody such that the antibody is taken up by neurons in the brain.

2. The method of claim 1 , wherein expression of the transgene is driven by the endogenous albumin promoter.

3. The method of claim 1 , wherein the transgene is a fusion protein comprising amino acids encoded by the transgene and by the endogenous albumin gene.

4. The method of claim 1 , wherein the antibody is expressed in the serum and/or brain of the subject.

5. The method of claim 1 , wherein the AAV vector is an AAV2 vector.

6. The method of claim 5 , wherein the AAV2 vector is an AAV2/6 or AAV2/8 vector.

7. A genetically modified liver cell produced by the method of claim 1 .

Assignees

• Sangamo Biosciences Inc
• Sangamo Therapeutics Inc

Inventors

• Holmes Michael C
• Riley Brigit E

Classifications

• A61K48/0058 Primary

  Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C07K16/18

  against material from animals or humans · CPC title

• C07K2319/31

  fusions, other than Fc, for prolonged plasma life, e.g. albumin · CPC title